SHANGHAI PERHUM THERAPEUTICS

Shanghai PerHum Therapeutics is conducting a "study to evaluate the effect of chimeric antigen receptor (CAR) modified autologous T cells , CCT 303 in relapsed or refractory stage IV HER2 positive carcinoma. The dose escalation and dose expansion trials for safety, tolerability and antitumor activity in patients with advanced metastatic HER2 positive carcinoma, including gastric cancer, breast cancer, ovarian cancer and other solid tumors, is now recruiting. And if you meet the requirements, you will receive free treatment from Shanghai PerHum Therapeutics... Shanghai PerHum Therapeutics Co., Ltd, is a clinical-stage biotechnology company found in 2016. Closely working together with its affiliates-Exuma Biotech, PerHum is developing "Logic-gated" CAR-T platform to develop TME-restricted CAR-T therapies for solid tumors.

Also known as: Shanghai PerHum Therapeutics Co., Ltd.

Primary location: Shanghai